Canji: The lure of core technology

For some time, the idealized relationship between the pharmaceutical and biotech sectors has been one in which the pharma side accesses biotech products and expertise through corporate partnerships that maintain the independence of the biotech companies.

That probably remains true for product-type deals. But the growing number of biotech acquisitions indicates that in core technologies, such as screening, combinatorial chemistry and gene therapy, many pharmaceutical companies prefer outright ownership.